Acute Respiratory Distress Syndrome News and Research

RSS

ARDS may not be the primary lung iInjury in COVID-19

A new Italian study published on the preprint server medRxiv in August 2020 shows that this may not be an adequate explanation, since ARDS is a nonspecific diagnosis. Instead, they say, antemortem lung biopsy shows a “Covid pattern” of acute lung injury, which could guide the application of therapeutics.

16 Aug 2020

COVID-19 during pregnancy shows no affect on placental structure and pathology

A new study published on the preprint server medRxiv in August 2020 shows that the placenta in pregnant women infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) does not show any signs of abnormality that can be attributed to the infection.

14 Aug 2020

Experimental COVID-19 vaccine prevents severe disease in mice

Now, a novel experimental vaccine that is made from a mild virus genetically-modified to carry an essential gene from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronary disease (COVID-19), has shown promise in preventing pneumonia in mice infected with the virus.

14 Aug 2020

JAK inhibitors or type I interferon shown to reduce mortality in COVID-19

Now, a new study by researchers at Yale University and published on the preprint server medRxiv in August 2020 reports that the use of two drug categories, namely, JAK inhibitors and Type I interferons (IFNs), is associated with a dramatic improvement in mortality in COVID-19.

13 Aug 2020

Cardiovascular disease in COVID-19

The current COVID-19 pandemic is a primarily respiratory illness, manifesting with severe hypoxia and often progressing to acute respiratory distress syndrome (ARDS) and death. However, it is also known to be linked to a wide range of cardiovascular (CV) manifestations that are associated with a very poor prognosis.

13 Aug 2020

Study: High blood sugar may trigger worse outcomes in COVID-19 patients

As COVID-19 continues to rage across the U.S., researchers are digging deeper into how the virus wreaks havoc on the body, especially for those with a pre-existing chronic illness.

12 Aug 2020

Persistent hiccups an unusual COVID-19 symptom

Now, a team of researchers revealed another atypical symptom reported by patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronavirus disease (COVID-19) – persistent hiccups.

10 Aug 2020

DHODH inhibitor PTC299 shows potential as a COVID-19 therapeutic

As COVID-19 continues to take a heavy toll on human health and life in many parts of the world, there is still no effective antiviral drug or vaccine. This has fueled an intensive search for small molecules and proteins that can inhibit viral entry and replication.

10 Aug 2020

Advanced analysis offers new insights into immune system’s role in severe COVID-19

By conducting advanced analyses of immune system activation in patients with severe COVID-19, researchers at Karolinska Institutet have managed to identify several cell types that play a key part in the immune response to the new coronavirus and the hyperinflammation seen in severe cases of the disease.

7 Aug 2020

COVID-19 in pregnancy - premature birth common

A new study conducted by researchers at Yonsei University College of Medicine, Korea, suggests that while having coronavirus disease 2019 (COVID-19) during pregnancy has little effect on fetal or neonatal mortality, it can be associated with premature birth and sometimes severe outcomes for mother and baby, including death.

6 Aug 2020

Study provides comprehensive update on ACE2 enzyme with key role in SARS-CoV-2 infection

Researchers at Uppsala University have described the presence, throughout the human body, of the enzyme ACE2.

5 Aug 2020

New peptide molecule offers hope for emphysema

Emphysema is a progressive, debilitating lung disease in which the lung's breathing sacs, or alveoli, enlarge, get thinner, and eventually are destroyed as the cells die off. It can be fatal, and there is currently no cure.

4 Aug 2020

Photonics-based device could help COVID-19 patients with adequate treatments

Few could have foreseen the considerable impact that SARS-CoV-2 has had so far and is still having worldwide. Numbers continue to escalate and the complexity of the COVID-19 symptoms have hindered all efforts to optimize its treatment.

3 Aug 2020

Researchers report a liquid biopsy for COVID-19

A new study published on the preprint server medRxiv in July 2020 reports the potential of cell-free DNA as a marker of the severity of disease in COVID-19. This could help triage patients as well as provide a prognostic marker.

30 Jul 2020

Scientists develop human lung organoids to study SARS-CoV-2 infection

Now, a new study published on the preprint server bioRxiv in July 2020 reports the development of a human distal lung culture system that can be functionally tested. This will help not only to understand how this infection produces disease but also to test the proliferative capacity of the stem cells in this part of the body.

30 Jul 2020

Anti-inflammatory Tetracycline activity may modulate COVID-19 severity

The current COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), seems to attack the human airway epithelium primarily. In severely affected patients, the illness progresses to hypoxemic respiratory failure and acute respiratory distress syndrome (ARDS). The latter is treatable mainly by supportive management.

30 Jul 2020

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Avacta Group plc, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co.Ltd and AffyXell Therapeutics.

29 Jul 2020

Researchers identify anticoagulation agent that suppresses SARS-CoV-2 replication in vitro

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can cause acute respiratory distress syndrome, hypercoagulability, hypertension, and multiorgan dysfunction.

27 Jul 2020

Higher levels of TGFBIp are correlated with severity of COVID-19 symptoms

A new study found raised levels of transforming growth factor beta-induced protein (TGFBIp) in blood sampled from roughly 100 people hospitalized for COVID-19, and further found that elevated levels of both the normal and acetylated forms of TGFBIp correlated with the severity of disease symptoms in these patients.

25 Jul 2020